Market Newsdesk

MCCARRAN, Nev., Dec. 08, 2020 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), which is reinventing lead recycling with its AquaRefining™ technology, announced the Company will participate in the 13th Annual LD Micro Main Event Conference. Aqua Metal’s Chief Executive Officer, Steve Cotton and Chief Financial Officer, Judd Merrill are scheduled to present at 2:00 p.m. EST (11:00 a.m. PST) on December 15, 2020. Interested parties may register for the event and access the webcast presentation through the following link: https://ve.mysequire.com/.     

About Aqua Metals

Aqua Metals, Inc. (NASDAQ: AQMS) is reinventing lead recycling with its patented AquaRefining™ technology. Unlike smelting, AquaRefining is a room temperature, water-based process that emits less pollution. The modular systems are intended to allow the Company to vastly reduce environmental impact and scale lead acid battery recycling production capacity by licensing the AquaRefining technology to partners. This could help meet the growing demand for lead to power new applications including stop/start automobile batteries which complement the vehicle’s main battery, lead acid batteries which are in electric vehicles, Internet data centers, alternative energy applications including solar, wind, and grid scale storage. Aqua Metals is based in McCarran, Nevada. To learn more, please visit www.aquametals.com.

Aqua Metals has used, and intends to continue using, its investor relations website (https://ir.aquametals.com), in addition to its Twitter, LinkedIn and YouTube accounts at https://twitter.com/AquaMetalsInc (@AquaMatalsInc), https://www.linkedin.com/company/aqua-metals-limited and https://www.youtube.com/channel/UCvxKNWcB69K0t7e337uQ8nQ respectively, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Safe Harbor

This press release contains forward-looking statements concerning Aqua Metals, Inc. Forward-looking statements include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects,” “contemplates,” “anticipates,” “plans,” “intends,” “believes”, “estimates”, “potential“ and variations of such words or similar expressions that convey uncertainty of future events or outcomes, or that do not relate to historical matters. The forward-looking statements in this press release include our expectations for the sale of the land and building at our McCarran facility; the sufficiency of any sale proceeds coupled with any further insurance recovery to fund our operations and the development and completion of our V1.25 electrolyzer; the benefits of the V1.25 electrolyzer; and the future of lead acid battery recycling via traditional smelters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (1) the risk that we may not be able to sell the land, building and non-core equipment at our McCarran facility on a timely basis, (2) the risk that we may not realize the sale proceeds we hoped for from the sale of the land, building and non-core equipment, (3) the risk that the terms of any such sale may include indemnities or other provisions that pose potential contingent liability to Aqua Metals, (4) the risk that we may not be able to complete the development of our V1.25 electrolyzer; (5) the risk that we may not realize the expected benefits from our V1.25 electrolyzer; (6) the risk that our insurance recovery from our claims relating to the November 2019 fire at our TRIC facility and proceeds from the sale of legacy assets will not be sufficient to fund our accelerated licensing strategy; (7) the risk that we may not be able to satisfactorily demonstrate to potential licensees the technical and commercial viability of our V1.25 electrolyzer and AquaRefining process; (8) the risk that licensees may refuse or be slow to adopt our AquaRefining process as an alternative to smelting in spite of the perceived benefits of AquaRefining; (9) the risk that we may not realize the expected economic benefits from any licenses we may enter into; (10) the risk that we will have to engage in additional sales of our equity securities in order to fund our future operations; (11) the risk that further funding, by any means, may not be available at all; (12) the fact that we have not generated any significant revenue to date, thus subjecting us to all of the risks inherent in an early-stage company; (13) the risk that our patents and any other patents that may be issued to it may be challenged, invalidated, or circumvented; (14) the risk that we may not be able to successfully conclude our proposed joint development agreement with Clarios or, if we do, realize the expected benefits of such agreement; (15) changes in the federal, state and foreign laws regulating the recycling of lead acid batteries; (16) our ability to protect our proprietary technology, trade secrets and know-how and (17) those other risks disclosed in the section “Risk Factors” included in our Quarterly Report on Form 10-Q filed on October 22, 2020 and subsequent SEC filings. Aqua Metals cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

Contact: Glen Akselrod, Bristol Capital
(905) 326-1888, Ext. 1
[email protected] 

TORONTO, Dec. 08, 2020 (GLOBE NEWSWIRE) — Bragg Gaming Group (TSXV: BRAG, OTC: BRGGF) (“Bragg” or the “Company”) is pleased to announce that CEO Adam Arviv has been named to the prestigious Hot 50 of 2021 Rising Stars and Emerging Leaders list, by leading gaming industry publication Gaming Intelligence.

Mr. Arviv initially joined Bragg in 2018 as a strategic investor, working closely with the group’s management team to focus the company on international growth. He stepped into the CEO role in 2020 and has since engineered a complete transformation of the company into a global gaming force.

“We’re very excited to receive this recognition of Bragg’s ongoing transformation into a leading force in the gaming world,” said Mr. Arviv. “Gaming Intelligence is a top industry publication, and we’re especially pleased to receive these accolades from such a highly respected source.”

Bragg has grown exponentially over the past two years, most recently achieving 72 per cent revenue growth in the third quarter year-over-year. The Company has also added more than 30 new significant customers in 2020.

About Bragg Gaming Group

Bragg Gaming Group Inc. (TSXV: BRAG, OTC: BRGGF) is a next generation gaming group with cutting-edge technology, leading brands and world-class management expertise, developing into a global gaming force. Formed by a team of gaming industry experts, Bragg’s main portfolio asset is ORYX Gaming, an innovative business-to-business i-gaming platform, product aggregator, casino content, managed sportsbook and managed services provider.

Through this brand and targeted acquisitions, Bragg is focused on becoming a leader within the evolving global gaming industry. Learn more at https://www.bragg.games.

For Bragg Gaming Group, contact:

Yaniv Spielberg, CSO, Bragg Gaming Group
[email protected]

For media enquiries or interviews, please contact:

Kelly Morgan
[email protected]

For investor inquiries, please contact:

Tim Dawson, Bragg Gaming Group
[email protected]

Cautionary Statement Regarding Forward-Looking Information

This news release may contain forward-looking statements or “forward-looking information” within the meaning of applicable Canadian securities laws (“forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or describes a “goal”, or variation of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

All forward-looking statements reflect the Company’s beliefs and assumptions based on information available at the time the statements were made. Actual results or events may differ from those predicted in these forward-looking statements. All of the Company’s forward-looking statements are qualified by the assumptions that are stated or inherent in such forward-looking statements, including the assumptions listed below. Although the Company believes that these assumptions are reasonable, this list is not exhaustive of factors that may affect any of the forward-looking statements. The key assumptions that have been made in connection with the forward-looking statements include the following: the impact of COVID-19 on the business of Bragg; the countercyclical growth of the business of Bragg; the regulatory regime governing the business of Bragg; the operations of the Company; the products and services of the Company; Bragg’s customers; acquisition opportunities; the growth of Bragg’s business, which may not be achieved or realized within the time frames stated or at all; and the anticipated size and/or revenue associated with the gaming market globally.

Forward-looking statements involve known and unknown risks, future events, conditions, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, prediction, projection, forecast, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, the following: risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; the inability to access sufficient capital from internal and external sources; the inability to access sufficient capital on favorable terms; realization of growth estimates, income tax and regulatory matters; the ability of Bragg to implement its business strategies; competition; economic and financial conditions, including volatility in interest and exchange rates, commodity and equity prices; the estimated size of the gaming market globally; changes in customer demand; disruptions to our technology network including computer systems and software; natural events such as severe weather, fires, floods and earthquakes; and risks related to health pandemics and the outbreak of communicable diseases, such as the current outbreak of COVID-19.

Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise, except in accordance with applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

– AMMO Estimates Record Sales of $55 million or 272% Increase Year-Over-Year

– AMMO listed on NASDAQ

SCOTTSDALE, Ariz., Dec. 08, 2020 (GLOBE NEWSWIRE) — AMMO, Inc. (NASDAQ: POWW) (“AMMO” or the “Company”), a premier American ammunition and munition components manufacturer and technology leader, is providing a corporate update amidst unprecedented demand in the U.S. domestic and International commercial ammunition markets.

AMMO has a current record backlog of $135 million in booked orders as of December 1, 2020—the largest in Company history. “Our record backlog has continued to grow, with booked orders coming in across all channels,” said Fred Wagenhals, AMMO’s CEO. “We continue to expand our footprint with retailers across the country while continuing to build brand awareness and loyalty with customers.”

Financial Summary for Fiscal Second Quarter 2021 vs. Fiscal Second Quarter 2020

• Total revenue increased 307% to $12 million compared to $2.9 million.
  • Ammunition revenue increased 564% to $8.7 million.
  • Casing revenue increased 100% to $3.3 million.

Guidance for Fiscal Third Quarter 2021 vs. Fiscal Third Quarter 2020

• Total revenue estimate increased 435% to $15 million compared to $2.8 million.
• 25% increase in revenue when compared to $12 million in the 2nd quarter of fiscal 2021.

Guidance for Fiscal Year 2021 vs. Fiscal Year 2020

• Total revenue estimate increased to $55 million compared to $14.8 million.
• Year-over-year revenue growth rate of 272%

“We expect positive adjusted EBITDA to significantly increase over the next several quarters as we continue to maintain our focus on driving sales of our higher margin product offerings and enhancing manufacturing efficiencies across our entire product portfolio,” said Fred Wagenhals, AMMO’s CEO.

AMMO Announces Pricing of $18 Million Upsized Public Offering of Common Stock and Concurrent Uplisting to The Nasdaq Capital Market^™

• As of December 1, 2020, AMMO’s common stock is listed on The Nasdaq Capital Market^® (“NASDAQ”) under its pre-uplisting “POWW” ticker symbol.
• The Company successfully closed an approximate $18 million offering at $2.10 per share on December 3, 2020.

“Our singular focus at AMMO is to upset the stagnant ammunition industry in order to drive long-term stockholder value. With the uplisting and strategic funding successfully completed, we will continue to implement our plans to strategically expand our operations as we continue to disrupt the industry with cutting-edge and technologically improved product offerings,” stated Mr. Wagenhals.

“Management is very excited for the future for the Company’s shareholders and the entire AMMO team. We anticipate significant growth in sales, increased margins and continuing positive adjusted EBITDA performance. AMMO enjoys a strong balance sheet that will allow us to pursue market opportunities as we prepare to turn the page on 2020 and move into 2021 better positioned to successfully compete for revenue across all product lines and sales channels. The NASDAQ listing increases our visibility in the investing community, enhancing our operational platform and ultimately benefitting our stockholders,” confirmed Mr. Wagenhals.

Forward Looking Statements

This document contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies, goals and objectives of management for future operations; any statements concerning proposed new products and services or developments thereof; any statements regarding future economic conditions or performance; any statements or belief; and any statements of assumptions underlying any of the foregoing.

Forward looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words, or the negative thereof. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures and risk factors we include in Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Reports filed on Form 8-K.

Investor Contact:

Rob Wiley, CFO
AMMO, Inc.
Phone: (480) 947-0001
[email protected]

Stem to Launch 12 New Products in January Featuring
, Cannabis-Infused Topicals,
and a new CBD Product Line-Up from Patent Edibles -Pending Hemp Genetics

Acquisition of Driven Deliveries to Support Distribution Drive

BOCA RATON, FL, Dec. 08, 2020 (GLOBE NEWSWIRE) — Stem Holdings, Inc. (OTCQX: STMHCSE:STEM), a leading vertically-integrated cannabis and hemp branded products company with state-of-the-art cultivation, processing, extraction, retail, and distribution operations throughout the United States, announced that they will be starting 2021 with an exciting line-up of disruptive products beginning in Oregon and launching in all markets in which Stem operates. Stem has added a cutting-edge extraction laboratory to its commercial kitchen capabilities for full integration in production of these value-added, margin-accretive products. The pending acquisition of Driven Deliveries, Inc. later this month (OTCQB: DRVD) will support new distribution in current and new markets.

Cannavore^™ Cannabis Confections – Just in time for the holidays, Stem’s Cannavore is launching two flavors for its award-winning caramels – Irish Cream and Hazelnut – two on trend flavors complementing our original Salted Caramel. Made with full spectrum solventless bubble hash, they are rich in cannabinoids and terpenes for consistent dosing and effectiveness.

Dose-ology^™ Topicals – To condition skin all year round, Stem’s Dose-ology brand is launching its first cannabis-infused topicals featuring lotion, massage oil, and facial serum. Made with THC concentrate from Stem’s own TJ Gardens award-winning brand of cannabis, Dose-ology will feature the exact dose recommended by Stem Medical Holdings’ team led by Dr. Drore Eisen, to assure consumers that they will experience optimal products benefits with each and every usage.

Dose-ology^™ CBD Topicals – Dose-ology will also enter the mass market with a line-up of four new broad-spectrum CBD-infused topical products that reflect Stem’s commitment to efficacious dosing and performance. They will initially be sold at select retailers and in e-commerce. The hemp grown for these products features patent-pending genetics that resist powdery mildew, and continues to be part of Stem’s work with Cornell University’s School of Agriculture.

“This is just the beginning of a new queue of disruptive products unlike any other company’s,” stated Adam Berk, CEO of Stem. “Our vertical integration from seed to extraction to production of finished goods distinguishes us from other brands in the marketplace, particularly as we leverage the expertise of our experience grow and extraction teams, and our increasing ability to fill distribution white space along with the upcoming direct-to-consumer capability offered by Driven.” He continued, “We will be closing on our acquisition of Driven this month and this will be a critical component of our go-to-market strategy, as will strategic collaborations to enthuse the market,” Berk concluded.

About Stem Holdings, Inc.

Stem Holdings, Inc. (OTCQX: STMH CSE: STEM) is a leading cannabis and hemp branded products company in the U.S. with proprietary capabilities in sustainable cultivation, processing, extraction, and R&D, as well as retail and distribution operations aligned with state-by-state regulations. Stem’s award-winning brands are the foundation of the Company’s expansion into current and new segments and markets, with exceptional and disruptive brands and products that benefit well-being. Stem’s expertise and scale will drive growth domestically and internationally, building value for shareholders.

Cautionary Note Regarding Forward-Looking Information

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the management of Stem with respect to future business activities. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and include information regarding: (i) the ability of the Company to successfully achieve its business objectives, (ii) plans for expansion of Stem, (iii) expectations for other economic, business, and/or competitive factors, and (iv) anticipated growth.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the management of Stem’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Stem believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws, including those related to taxation; the inability to locate and acquire suitable companies, properties and assets necessary to execute on the Company’s business plans; and increasing costs of compliance with extensive government regulation. This forward-looking information may be affected by risks and uncertainties in the business of Stem and market conditions.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Stem has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Stem does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

No securities regulatory authority has in any way passed upon the merits of the proposed transactions described in this news release or has approved or disapproved of the contents of this news release.

For further information, please contact:
Media Contact:
Mauria Betts
STEM HOLDINGS, INC.
[email protected]
971.319.0303

Attachment

• Stem Holdings, Inc

Presentation on Tuesday December 15^th at 11:00am EST

LOS ANGELES, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it will be presenting at the 13th annual LD Micro Main Event investor conference on Tuesday, December 15, 2020 at 11:00 AM EST / 8:00 AM PST. Amro Albanna, Co-founder and Chief Executive Officer of Aditxt, will be presenting to a live, virtual audience. 

Register here:


ve.mysequire.com/

The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts. 

“The time has finally come to do something different in the virtual conference world. Let’s see if we can pull off something that can be enjoyed by both executives and investors alike,” stated Chris Lahiji, Founder of LD, now a wholly owned subsidiary of SRAX, Inc.

The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform. 

View Aditxt’s profile here:


http://www.ldmicro.com/profile/ADTX

Profiles powered


by LD Micro

About Aditx Therapeutics

Aditxt is developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring biotechnology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming biotechnology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

About LD Micro/SEQUIRE

LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com.

The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe. 

In September 2020, LD Micro. Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:

PCG Advisory
Jeff Ramson
Chief Executive Officer
[email protected]
646-762-4518
www.aditxt.com

Source: Aditxt via LD Micro

NOT FOR DISTRIBUTION TO US NEWS WIRE SERVICES OR FOR DISSEMINATON INTO THE USA

VANCOUVER, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) — Independence Gold Corp. (TSX.V: IGO) (the “Company”) wishes to announce a proposed equity financing (the “Financing”) comprised of 6,250,000 flow-through common shares (the “FT Shares”) at a price of $0.16 per FT Share, for aggregate proceeds of $1,000,000; and 3,571,428 additional common shares (each a “Unit”) at a price of $0.14 per Unit for aggregate proceeds of $500,000. Each Unit will consist of one common share of the Company (a “Share”) and one half of one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one additional Share at an exercise price of $0.20 per common share for a period of 24 months. Subject to compliance with applicable securities laws and the approval of the Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.

The net proceeds from the Offering will be used by the Company to fund a winter drill program at the 3Ts Property, expected to commence in February 2021, and may also be used for general and administrative purposes.

Closing of the Offering is subject to receipt of applicable regulatory approvals including the approval of the TSX Venture Exchange. The securities issued will be subject to a standard four month hold period.

ON BEHALF OF THE BOARD of Independence Gold Corp.

“Randy Turner”

Randy Turner, President and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to Independence within the meaning of applicable securities laws, including statements with respect to the Company’s planned drilling and exploration activities. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in Independence’s public filings under Independence Gold Corp.’s SEDAR profile at

www.sedar.com

.  Although Independence has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Independence disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

UNITED STATES ADVISORY. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), have been offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

For further information please contact Randy Turner at 604-687-3959 or [email protected]. 

HPN424
has
show
n
confir
med partial response in treatment of
metastatic castration
–
resistant prostate cancer
in highest
fixed
dose cohort
(160 ng/kg)
of continuing Phase 1
/2a
d
o
se escalation
trial

Three of seven patients in highest
fixed
dose HPN424 cohort have shown PSA reduction

D
ose escalation
trials
advancing for HPN536 and HPN217 with initial data readouts
and
initiation of expansion cohorts
expected in 2021

Management to host
clinical
update
webcast/
c
all
today,
D
ecember
8
, 2020
,
at 8
a.m. ET

SOUTH SAN FRANCISCO, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) —  Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provided a pipeline update and reported a confirmed partial response based on RECIST v1.1 criteria for its most advanced program, HPN424 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). As of December 1, 2020, in the 160ng/kg cohort, which is the highest fixed dose tested to date, 7 patients have been enrolled and one patient has achieved a confirmed partial response. In addition, 3 patients enrolled in this cohort had serum PSA reductions, including one with a reduction of 50% (PSA50). Dose escalation continues in this trial, in the Phase 1/2a clinical trials for HPN536 as a treatment for ovarian cancer and other mesothelin-expressing solid tumors and in the HPN217 Phase 1/2 clinical trial for multiple myeloma. Step dosing is being utilized in all programs to accelerate testing of higher doses. Dosing of the first patient in the Phase 1/2 trial for Harpoon’s fourth TriTAC development program, HPN328, in small cell lung cancer and other DLL3-associated tumors is expected to occur by the end of the year.

”We are pleased to provide a trial update to our shareholders today, as well as outline our expectations for 2021. We have made significant progress in all of our clinical development programs in 2020,” stated Gerald McMahon, Ph.D., President and CEO of Harpoon Therapeutics. “We are excited to report our first confirmed partial response in the continuing dose escalation trial for HPN424, especially in a heavily pretreated patient population with advanced metastatic disease. We are also excited by the potential for multiple data releases in 2021 on all four of our programs, which we believe represent meaningful milestones for our company.”

“We are pleased to report the activity we are seeing with HPN424 in late-stage prostate cancer patients in our highest fixed dose cohort tested to date,” said Natalie Sacks, M.D., Chief Medical Officer of Harpoon. “We are implementing step dosing in all of our programs, which allows rapid escalation to higher doses. We look forward to sharing data from these higher-dose cohorts in 2021.”

Clinical Program Updates

(All data as of December 1, 2020)

Dose escalation
continues
in Phase 1/2
a
trial for HPN424 in the treatment of
mCRPC
. As of the December 1, 2020 data cutoff date, 69 patients have been dosed across 14 cohorts at fixed doses of 1.3 to 160ng/kg and in step dosing cohorts up to 300ng/kg administered as a weekly intravenous infusion. Enrolled patients had a median of 6 prior systemic therapies, and 76% of patients had prior chemotherapy in the metastatic castration-resistant setting. Ten of 44 patients (23%) with treatment start dates at least 6 months ago remained on study treatment for more than 24 weeks.

At the highest fixed dose tested to date, 160ng/kg, one patient out of 7 has experienced a confirmed partial response with tumor lesion reduction of 43%, and 3 of 7 patients have had serum PSA declines from baseline, including one patient with a PSA reduction greater than 50%.

HPN424 was generally well tolerated and cytokine-related adverse events have been manageable. Reported Grade 3 or higher adverse events have included cytokine release syndrome (CRS) (10%), ALT increase (11%) and AST increase (11%). CRS events and transaminitis have been transient and have not resulted in treatment discontinuation. Dose-limiting toxicities (DLTs) have been observed and have not limited escalation. A maximum tolerated dose (MTD) has not been identified. Presentation of Phase 1 data and initiation of an expansion cohort is planned for the first half of 2021. Interim data from this expansion cohort is anticipated by the end of 2021.

HPN536
(
mesothelin
TriTAC
)
Phase 1/2a clinical trial
continues escalation. Dosing has occurred across 9 fixed-dose cohorts of 6 to 280ng/kg and 1 step dose cohort up to 600ng/kg. Tumor types treated include late-stage ovarian and pancreatic cancers and peritoneal mesothelioma. Enrolled patients had a median of four prior systemic therapies, and 66% of patients had progressive disease as best response to their most recent prior therapy. Pharmacokinetic analysis shows median half-life of more than 70 hours. Among the relapsed/refractory ovarian cancer patients with at least one post-baseline scan, 8 of 12 (67%) patients showed stability of target lesions.

HPN536 appears to be well tolerated. One CRS grade 3 occurred in the absence of dexamethasone premedication treatment. The CRS resolved, and the patient continued on study with dexamethasone premedication. As of December 1, 2020, no DLTs have been observed. Initiation of an expansion cohort is anticipated by the second half of 2021, with a presentation of Phase 1 data by year-end 2021.

Dose escalation for HPN217
(BCMA
TriTAC
)
Phase 1/2 clinical trial progressing
rapidly
. Relapsed/refractory multiple myeloma patients have been treated across 6 single-patient fixed dose cohorts of 5 to 810µg, reflecting a more than 100-fold increase in dose in 8 months. HPN217 has been well-tolerated, and no DLTs have been observed as of the December 1, 2020 cutoff date. A presentation of interim data is anticipated in 2021, with initiation of a dose expansion cohort in the second half of 2021.

First patient dosing anticipated for HPN
328 (DLL3
TriTAC
)
by the end of 2020. The first site is open and recruiting for the dose escalation portion of this Phase 1/2 clinical trial. In the first cohort, the patients will receive a flat dose of 15µg of HPN328 administered once weekly by intravenous infusion. Eligible patients include small cell lung cancer patients who have relapsed after platinum chemotherapy and patients with other tumors associated with DLL3 expression. Presentation of initial data is planned for the second half of 2021.

Webcast and Conference Call

Harpoon’s management will host a webcast and conference call at 8 a.m. ET / 5 a.m. PT on December 8, 2020. The live call may be accessed by dialing (866) 951-6894 for domestic callers and (409) 216-0624 for international callers with conference ID code number 1388395. A webcast of the live call will be available online in the investor relations section of the Harpoon website at www.harpoontx.com. A replay of the webcast will be available shortly after the event and can be accessed at the same weblink.

About
Harpoon
Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC^®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and Harpoon plans to initiate a Phase 1/2 trial in the fourth quarter of 2020. Harpoon has also developed a proprietary ProTriTAC^TM platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope, design and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, and the timing of development milestones for product candidates. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials, the risk that trials may be delayed and may not have satisfactory outcomes, and unexpected litigation or other disputes that impede clinical trial progress. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts
:

Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
[email protected]

Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
[email protected]

LYON, France and NEWTON, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration whereby both companies will work together to test and optimize growth hormone receptor antagonist (GHRA) peptides, with the goal of selecting a candidate for clinical development as a potential treatment for acromegaly, a rare but serious endocrine disorder with significant unmet medical need. Amolyt has also acquired an option to license the identified candidates for future clinical development.

“We are pleased to partner with PeptiDream, a leading Japanese biopharmaceutical company with an impressive technology platform for the design of new therapeutic peptides, and whose strategic partners include world class pharmaceutical companies,” stated Thierry Abribat, Ph.D., chief executive officer of Amolyt Pharma. “The potential expansion of our pipeline into acromegaly, where significant unmet need persists, represents a perfect strategic fit for Amolyt. Given our extensive experience in developing therapeutic peptides, including AZP-3601, our lead clinical candidate for hypoparathyroidism, we will leverage our expertise to bring a promising therapy to acromegaly patients in need.”    

Patrick Reid, chief executive officer of PeptiDream Inc., added, “We believe Amolyt Pharma is the ideal partner to lead the development of our small peptide GHRA platform and to potentially bring an improved treatment paradigm to patients suffering from acromegaly. We are impressed by Amolyt’s therapeutic peptide development capabilities and we are confident in entrusting them with advancing this potentially important asset. We look forward to a mutually beneficial partnership.”

About Acromegaly
Acromegaly is a rare chronic endocrine disorder that is typically caused by an adenoma (benign tumor) of the pituitary gland, and that is characterized by excessive production of growth hormone (GH), resulting in abnormally high levels of insulin-like growth factor-1 (IGF-1). Common features include enlargement of the hands, feet and jaw. Medical complications include cardiovascular disease, cardiomyopathy that can potentially lead to heart failure, impaired glucose tolerance with subsequent development of diabetes, hypogonadism, bone and joint disease, cerebrovascular events, sleep apnea and impaired respiratory function. The mean age of diagnosis is 40-45 years, but it is often diagnosed 4-10 years after onset due to its slow progression. It is estimated that there are 26,000 acromegaly patients in the U.S. and an additional 35,000 in the E.U.

About
Amolyt
Pharma 

Amolyt Pharma is building on its team’s established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Its portfolio includes AZP-3601, a potential treatment for hypoparathyroidism, and AZP-3404, which is undergoing indication prioritization work. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit www.amolytpharma.com or follow us on Twitter at @AmolytPharma.

At
Amolyt
:

Media:

Cherilyn Cecchini, M.D.
LifeSci Communications
[email protected]
+1.646.876.5196

Investors:

Ashley Robinson
LifeSci Advisors, LLC
[email protected]
+1.617.430.7577

JERSEY CITY, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) — Verisk (Nasdaq:VRSK), a leading data and analytics company, announced today that Nationwide has joined the Verisk Cyber Data Exchange as part of a growing effort across the insurance industry to gain new insights into the rapidly changing world of cyber risk.

By joining the Verisk Cyber Data Exchange, Nationwide will contribute premium and loss records to an expanding pool of aggregated, anonymized insurance data from participating cyber insurers around the world. In return, Nationwide will obtain access to an interactive platform powered by the Exchange and be able to use its robust analytics to better manage risks, develop products, build models, and guide strategic planning.

“Understanding industry-wide cyber exposure and developing insights into pricing and loss trends is a major challenge in today’s dynamic cyber risk landscape,” said Catherine Rudow, Nationwide’s E&S/Specialty vice president of cyber insurance. “Joining the Verisk Cyber Data Exchange will improve our access to critical cyber insurance data and risk information, enabling us to deliver more robust cyber protections and further expand our leading risk solutions for consumers and businesses of all sizes.”

“Improving the collective understanding of cyber risk is a critical step toward building a thriving marketplace for cyber insurance coverages that ultimately protect consumers and businesses alike,” said Prashant Pai, vice president and general manager, Verisk Cyber Solutions. “With leading insurers like Nationwide participating in this important initiative, we can provide one-of-a-kind market intelligence to insurers looking to provide or enhance their cyber risk solutions.”

The Cyber Data Exchange is a part of Verisk’s Cyber Solutions Suite, an end-to-end ecosystem that can help insurers and reinsurers more quickly deliver new cyber programs or enhance existing solutions. Powered by data on more than 100 million organizations worldwide, the suite provides a wide range of products and services, including a pricing, underwriting, and distribution platform; advisory policy language and loss costs; an applicant analytics and scoring solution; a portfolio visualization engine; and aggregation management modeling for cyber risk.

To learn more about the Verisk Cyber Data Exchange, please visit: https://www.verisk.com/insurance/products/cyber-data-exchange/

To learn more about Nationwide’s cyber security offerings, please visit: https://mls.nationwideexcessandsurplus.com/fs/products/cyber-and-professional-liability/

About Verisk 

Verisk (Nasdaq:VRSK) is a leading data analytics provider serving customers in insurance, energy and specialized markets, and financial services. Using advanced technologies to collect and analyze billions of records, Verisk draws on unique data assets and deep domain expertise to provide first-to-market innovations that are integrated into customer workflows. Verisk offers predictive analytics and decision support solutions to customers in rating, underwriting, claims, catastrophe and weather risk, global risk analytics, natural resources intelligence, economic forecasting, and many other fields. Around the world, Verisk helps customers protect people, property, and financial assets.

Headquartered in Jersey City, N.J., Verisk operates in 30 countries and is a member of Standard & Poor’s S&P 500^® Index and part of the Nasdaq 100 Index.

In 2018 and 2019, Forbes magazine named Verisk to its World’s Best Employers list. For more information, please visit www.verisk.com.

About Nationwide

Nationwide, a Fortune 100 company based in Columbus, Ohio, is one of the largest and strongest diversified insurance and financial services organizations in the United States. Nationwide is rated A+ by both A.M. Best and Standard & Poor’s. An industry leader in driving customer-focused innovation, Nationwide provides a full range of insurance and financial services products including auto, business, homeowners, farm and life insurance; public and private sector retirement plans, annuities and mutual funds; excess & surplus, specialty and surety; pet, motorcycle, and boat insurance. For more information, visit www.nationwide.com. Follow us on Facebook and Twitter.

# # # #

Media Contacts:

Joseph Madden
Verisk Public Relations
201-232-4486
[email protected]

Brett Garrison
Edelman (for Verisk)
212-639-4903
[email protected]

Lyndsey Kleven
Nationwide Public Relations
614-507-0485
[email protected]